Free shipping on all orders over $ 500
Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) is a PPARγ agonist that provides high transcriptional potency by stabilizing the PPARγ (AF-2) coactivator binding surface and enhancing coactivator binding capacity. Leriglitazone (Hydroxypioglitazone) binds to PPARγC (LBD) with a Ki value of 1.2 μM and induces PPARγ (LBD) transcriptional efficiency with an EC50 of 680 nM.
| Molecular Weight | 372.44 |
| Formula | C19H20N2O4S |
| CAS Number | 146062-44-4 |
| Solubility (25°C) | N/A |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Ludger Schls. Lancet Neurol. Leriglitazone: frustration and hope in adrenoleukodystrophy
| Related PPAR Products |
|---|
| AZD-9574
AZD-9574 is a potent blood-brain barrier permeability inhibitor of PARP1, showing > 8,000 times selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 selectively inhibits PARP1 at the SSB site. AZD-9574 is an anticancer compound that can be used in HRD+ breast cancer and advanced solid malignancies. |
| Balofloxacin Dihydrate
an agonist of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway |
| Choline Fenofibrate
Choline fenofibrate is a newly developed choline salt of fenofibric acid, a synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity that acts as an PPARα agonist. |
| Saroglitazar Magnesium
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively. |
| GW1929
GW1929 is a potent PPAR-γ agonist, with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
